US Patent Issued to HANGZHOU TIANLONG PHARMACEUTICAL on Oct. 6 for "Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,753,409, issued on Oct. 6, was assigned to HANGZHOU TIANLONG PHARMACEUTICAL Co. LTD. (Hangzhou, China).

"Double-stranded RNAi agents for targeting and regulating HBV gene expression, and a use thereof" was invented by Zeao Huang (Hangzhou, China), Gengshen Song (Hangzhou, China), Shuo Yang (Hangzhou, China), Yang Yang (Hangzhou, China), Zhikang Tian (Hangzhou, China), Yucheng Wu (Hangzhou, China), Kai Xiong (Hangzhou, China) and Zhongcai Gao (Hangzhou, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides a double-stranded RNAi agent for targeting and regulating HBV gene expression and a use thereof. The double-stranded RNA...